MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$3,387,527
Unit: Dollar
Positive Cash Flow Breakdown
Proceeds from sale of common sto...
Accounts payable, accrued expens...
Stock based compensation
Others
Negative Cash Flow Breakdown
Net loss
Proceeds from exercise of warran...
Prepaid expenses and other curre...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-09-30
2025-06-30
Net loss
-3,027,733
4,944,343
-1,873,669
-4,704,147
Change in fair value of warrant liability
-
-
0
-858
Change in fair value of investment option liability
-
-
0
1,707
Loss on write-off of deferred offering costs
0
19,597
-
-
Stock based compensation
125,114
-498,416
186,981
400,108
Amortization of intangibles
-
-
0
42,180
Depreciation expense
36,826
-81,953
40,369
78,824
Other
-
-
-128,683
-
Due to related parties
26,750
133,016
-99,875
-133,016
Prepaid expenses and other current assets
24,521
384,406
-84,603
-48,192
Accounts payable, accrued expenses and other current liabilities
419,025
-121,408
-284,682
-11,300
Net cash used in operating activities
-2,444,539
4,099,841
-2,074,956
-4,281,724
Proceeds from sale of common stock and warrants, net of offering costs
4,347,972
-3,039,674
0
4,244,467
Proceeds from the subscription receivable related to the issuance of inducement warrants and the exercise of warrants and preferred investment options
-
-
-
0
Proceeds from common stock sold for cash pursuant to the atm agreement, net of offering costs
-7,377
1,298,415
-
0
Payment for offering costs previously accrued
-
-
-
0
Proceeds from common stock sold for cash pursuant to the atm agreement, net of offering costs
-
-
1,058,300
578,499
Payment of deferred offering costs
18,838
-
-
-
Proceeds from exercise of warrants
-485,853
-
1,934,051
75,044
Net cash provided by financing activities
5,844,999
-5,387,153
2,992,351
4,898,010
Effect of foreign exchange rate on changes on cash
-12,933
2,022
-9,617
-7,496
Net increase in cash
3,387,527
-1,285,290
907,778
608,790
Cash at beginning of period
3,757,594
3,757,594
2,241,026
-
Cash at end of period
8,296,296
4,908,769
3,757,594
-
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from sale of
common stock and...
$4,347,972
(2.44%↑ Y/Y)
something is missing
$2,009,095
Net cash provided by
financing activities
$5,844,999
(19.33%↑ Y/Y)
Canceled cashflow
$512,068
Net increase in cash
$3,387,527
(456.44%↑ Y/Y)
Canceled cashflow
$2,457,472
Proceeds from exercise of
warrants
-$485,853
(-747.42%↓ Y/Y)
Payment of deferred
offering costs
$18,838
Proceeds from common
stock sold for cash...
-$7,377
(-101.28%↓ Y/Y)
Accounts payable,
accrued expenses and...
$419,025
(3808.19%↑ Y/Y)
Stock based
compensation
$125,114
(-68.73%↓ Y/Y)
Depreciation expense
$36,826
(-53.28%↓ Y/Y)
Due to related
parties
$26,750
(120.11%↑ Y/Y)
Net cash used in
operating activities
-$2,444,539
(42.91%↑ Y/Y)
Effect of foreign
exchange rate on changes...
-$12,933
(-72.53%↓ Y/Y)
Canceled cashflow
$607,715
Net loss
-$3,027,733
(35.64%↑ Y/Y)
Prepaid expenses and
other current assets
$24,521
(150.88%↑ Y/Y)
Buy us a coffee
Enveric Biosciences, Inc. (ENVB)
Enveric Biosciences, Inc. (ENVB)